Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8817695rdf:typepubmed:Citationlld:pubmed
pubmed-article:8817695lifeskim:mentionsumls-concept:C1512505lld:lifeskim
pubmed-article:8817695lifeskim:mentionsumls-concept:C0074825lld:lifeskim
pubmed-article:8817695lifeskim:mentionsumls-concept:C0441472lld:lifeskim
pubmed-article:8817695pubmed:issue2-4lld:pubmed
pubmed-article:8817695pubmed:dateCreated1996-12-5lld:pubmed
pubmed-article:8817695pubmed:abstractTextA number of lines of evidence suggest that IGFs are important mitogens in human breast cancer: (1) IGFs are the most potent growth factor in human breast cancer cells; (2) estrogen stimulates expression of IGF-II and the type 1 IGF receptor; and (3) stromal cells express IGFs, which may act in a paracrine manner. Numerous studies have demonstrated that IGFBPs modulate the mitogenic effects of IGFs in the local environment. In particular, we have recently demonstrated that IGFBP-3 inhibits the growth of Hs578T and MDA-MB-231 human breast cancer cells in an IGF-independent manner. Further studies revealed the existence of cell surface-associated IGFBP-3 receptors. Receptor binding and the subsequent antiproliferative action of IGFBP-3 was inhibited by IGFs, owing to the formation of an IGF-IGFBP-3 complex that prevents the binding of IGFBP-3 to its receptors. In addition, exogeneously added soluble heparin or heparan sulfate inhibited the binding of IGFBP-3 to the cell surface in a dose-dependent manner. However, when heparin and heparan sulfate linkages of glycosaminoglycans on the cell surface were enzymatically remove, IGFBP-3 binding was only minimally affected. These data suggest that soluble heparin or heparan sulfate forms a complex with IGFBP-3, thereby inhibiting receptor binding of IGFBP-3, rather than competing with cell-surface glycosaminoglycans for binding of IGFBP-3. Additionally, the role of IGFBP-3 in the antiproliferative effects of transforming growth factor (TGF)-beta and retinoic acid (RA) is supported by our observations that: (1) inhibition of IGFBP-3 gene expression using an IGFNBP-3 antisense oligodeoxynucleotide not only blocks TGF-beta and RA simulation of IGFBP-3 production by up to 90%m but also inhibits their antiproliferative effects by 40-60%; and (2) treatment with IGF-II and IGF-II analogs diminish TGF-beta effects by blocking TGF-beta induced binding of IGFBP-3 to the cell surface. Taken together, our results support the hypothesis that IGFBP-3 is an important antiproliferative factor in human breast cancer, acting in an IGF-independent manner in addition to its ability to modulate the binding of IGF peptides to IGF receptors.lld:pubmed
pubmed-article:8817695pubmed:languageenglld:pubmed
pubmed-article:8817695pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8817695pubmed:citationSubsetIMlld:pubmed
pubmed-article:8817695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8817695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8817695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8817695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8817695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8817695pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8817695pubmed:statusMEDLINElld:pubmed
pubmed-article:8817695pubmed:issn0955-2235lld:pubmed
pubmed-article:8817695pubmed:authorpubmed-author:MüllerH LHLlld:pubmed
pubmed-article:8817695pubmed:authorpubmed-author:PEUUlld:pubmed
pubmed-article:8817695pubmed:authorpubmed-author:RosenfeldR...lld:pubmed
pubmed-article:8817695pubmed:authorpubmed-author:RUER ERElld:pubmed
pubmed-article:8817695pubmed:authorpubmed-author:GucevZZlld:pubmed
pubmed-article:8817695pubmed:issnTypePrintlld:pubmed
pubmed-article:8817695pubmed:volume6lld:pubmed
pubmed-article:8817695pubmed:ownerNLMlld:pubmed
pubmed-article:8817695pubmed:authorsCompleteYlld:pubmed
pubmed-article:8817695pubmed:pagination503-12lld:pubmed
pubmed-article:8817695pubmed:dateRevised2005-11-16lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:meshHeadingpubmed-meshheading:8817695-...lld:pubmed
pubmed-article:8817695pubmed:year1995lld:pubmed
pubmed-article:8817695pubmed:articleTitleAntiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells.lld:pubmed
pubmed-article:8817695pubmed:affiliationDepartment of Pediatrics, School of Medicine, Oregon Health Sciences University, Portland 97201-3042, USA.lld:pubmed
pubmed-article:8817695pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8817695pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8817695lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8817695lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8817695lld:pubmed